All posts by CAC2

Pediatric Cancer Advocacy Success and Plans for Childhood Cancer Action Days

Let's Get Geared Up for Action Day!   In our April CAC2 All-Member webinar, Danielle Leach, Co-Chair of the Alliance for Childhood Cancer presented information about the status of the STAR Act which passed through the Senate last month and about Childhood Cancer Action Days scheduled for later this month in Washington DC. Dr. Volchenboum graciously allowed us to share his slide deck as well. Pediatric_Data_Commons Read more

How Patient Driven Philanthropy is Driving Collaboration and Progress

In February’s All-Member webinar, CAC2 members Joanne Salcido (Pediatric Brain Tumor Foundation) hosted Kristin Schneeman, Director of Programs at FasterCures, a center of the Milken Institute. Philanthropy can play an critical role as a catalyst for change in the medical research and development ecosystem. Over the last decade, many patient-driven foundations – big and small, old and new – have been taking a more strategic and entrepreneurial approach to their role as research funders and are driving collaboration and progress for the patients they represent. In this webinar, Schneeman,presented about some of the new funding models and collaborative activities in which foundations [...] Read more

Germline Predisposition to Pediatric Cancer: It’s More Common Than You Think

In December's All-Member webinar, CAC2 members Ginger Diamond (Childhood Cancer Awareness Group of Coffee County) and Joanne Salcido (Pediatric Brain Tumor Foundation) hosted Dr. Sharon Plon from the Baylor College of Medicine, Texas Children's Hospital and Dr. Todd Druley of Washington University in St. Louis, speaking on pediatric cancer predisposition and genetic susceptibility. During this webinar, Drs. Sharon Plon and Todd Druley covered evidence suggesting that pediatric cancer, unlike adult cancers, has a significant contribution from germline genetic changes that skew normal childhood development. They also highlighted the approaches underway in the laboratory and clinic to address this issue including [...] Read more

The Role of the IRB in Clinical Trials: What Patients and Families Need to Know — SLIDE DECK

In this month's All-Member webinar, Joanne Salcido of the Pediatric Brain Tumor Foundation introduced and hosted Dr. Marjorie Speers of the WCG Foundation.  The slide deck from the presentation is linked below. Dr. Speers's presentation described the clinical trial process and the role of the IRB in phase 1 – 4 clinical trials. During her webinar, she explained the differences between academic and independent IRBs and the challenges IRBs face when they review multi-site trials. She also described the revised regulations that are likely to go into effect in 2018 and how they should help to reduce the time it takes for an [...] Read more

A Personalized Precision Approach to Therapy for Neuroblastoma

In this May's All-Member and Community Webinar, Gavin Lindberg (The EVAN Foundation) hosted physician investigators from the New Approaches to Neuroblastoma Therapy (NANT) clinical trials consortium who presented their work on defining genetic and biologic changes in a patient’s specific tumor that can be used to guide the development of novel more effective therapies, and the choice of therapy for an individual patient. They also discussed the implications of this approach to pediatric cancer in general. Dr. Shahab Asgharzadeh presented about New Approaches to Neuroblastoma Therapy (NANT) Precision Medicine Trial, identifying biomarkers for targeted and immune based therapies. Dr. Asgharzadeh [...] Read more

The Blood-Brain Barrier: What If You Could Get Drugs Across?

In this January 2017  CAC2 All-Member webinar, we provided an opportunity to our members, associate members, student members, and supporting organizations to learn about emerging technology using ultrasound and microbubbles to deliver therapeutic agents across the blood-brain barrier.  Clay Larsen, President & CEO and Rhodemann Li, Founder, EVP Strategy & Finance, both of Vesselon, presented about their plans for this technology in the pediatric brain tumor population. The blood-brain barrier (BBB) is the body's natural defense mechanism to prevent toxins from entering the brain.  Unfortunately, it also prevents 99% of all therapeutic molecules from getting to their target to treat many diseases, [...] Read more

The Canine-Kid Connection — SLIDE DECK

In this All-Member Webinar for November 2016, we provided an overview of the compelling case for studying and treating cancer in canine cancer patients – a model of spontaneously occurring disease - the underlying science, and its potential not only to help us better understand and treat pediatric cancer, but also to accelerate the pediatric cancer drug development process. CAC2 Member Ulrike Szalay of Canines -N-Kids explains:  "As we know too well, cancer is the #1 cause of disease-related death in children in most developed countries. At least 1 in 5 will die from their disease, while the vast majority [...] Read more

The Blue Ribbon Panel Report and Pediatric Cancer

Earlier this year, as part of Vice President Biden’s Cancer Moonshot initiative, the White House established a Blue Ribbon Panel of experts to report on the current challenges and opportunities facing cancer research. In this CAC2 Research Interest Group webinar for September1 2016, CAC2 welcomed Blue Ribbon Panel members Dr. Peter Adamson (Chair of the Children's Oncology Group) and David Arons (CEO of the National Brain Tumor Society) in a discussion of the panel’s recently issued report and its implications for pediatric cancer. Read more

Basics of a Clinical Trial in Pediatrics: A Sponsor’s Perspective

In this All-Member and all-community webinar for August 2016, CAC2 welcomes Drs. Michael Trigg, Brigid Bradley-Garelik, and Greg Plautz from Bristol-Myers Squib, speaking on the clinical trial process. These three esteemed industry experts will provide an overview of the clinical trial process, particularly from an industry-sponsored trial perspective and cover topics such as clinical trial designs, different required FDA phases of drug development, data monitoring committees, general principles of pediatric trials and special considerations of pediatric trials, industry obligations to pediatrics and personalized medicine. This presentation was not recorded. Read more